Curome BioSciences

Curome BioSciences is a South Korean clinical-stage biopharmaceutical company founded in 2017 that develops first-in-class treatments for rare and orphan diseases, with a primary focus on mitochondrial diseases, inflammation, and fibrosis. Its lead program, HK-660S, is a novel therapeutic for Primary Sclerosing Cholangitis (PSC) that has received U.S. FDA Orphan Drug Designation, FDA Fast Track Designation, and European ODD, and has completed Phase 2a clinical trials. The company is headquartered in Cheongju (Osong), South Korea, and has raised Series A and Series B funding from investors including KDB. Curome targets the global rare disease market with differentiated IP licensed or transferred from leading Korean universities.